Europe's 'FDA' in limbo as hidden costs of Brexit continue to mount
London-based European Medicines Agency's bid to relocate sends tremors through UK's drug industry, raises public-safety concerns
London
WHEN it switched offices in London not long ago, the European Medicines Agency (EMA) signed a 25-year lease on a shiny new building in the east of the city.
Just two years later, the organisation is preparing to relocate again, but this time its likely move has sent tremors through Britain's pharmaceutical industry and raised fears over public safety.
The uncertain fate of the EMA, which like the US Food and Drug Administration (FDA) oversees the approval of drugs for use across Europe, follows Britain's vote in June to leave the European Union (EU).
That surprise decision means the organisation, an EU agency, will almost certainly have to leave Brit…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
India’s inflation at risk from extreme weather, geopolitical issues: central bank
Thailand to replace military-appointed Senate, reduce its powers
Bankers lose hope of London IPO revival for another year
Decarbonisation schemes are generating hot air
BOJ will hike rates if trend inflation accelerates, says Ueda
India tells spice makers to give details of quality checks after Hong Kong allegations